← Leaderboards
Kole T Roybal
J. David Gladstone Institutes
$7,404,890
Attributed
$10,476,864
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$10,476,864 · 5
By mechanism
R01$6,143,949 · 3
DP2$2,415,750 · 1
U54$1,917,165 · 1
Top collaborators
- Bin Liu3 shared
- Alexander Marson3 shared
- David M Wilson3 shared
Most similar at J. David Gladstone Institutes
Same institution · by research overlap
- Alexander Marson$20,805,878
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorReceptorEngineeringT-LymphocyteMalignant NeoplasmsAntigensCytokineChimeric Antigen Receptor T CellsT Cell TherapyTreatment EfficacyTechnologyXenograft ModelEngineered T CellsIn VitroIn VivoImmuneCellsSolid NeoplasmImmune ResponseT-Cell ReceptorAntigen TargetingDesignSafetyCancer Therapy
Grant awards (11)
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy$749,187
R01 · FY2025 · CA
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors$666,268
R01 · FY2025 · CA · contact PI
Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking$659,855
R01 · FY2025 · CA · contact PI
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy$711,787
R01 · FY2024 · CA
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors$632,874
R01 · FY2024 · CA · contact PI
Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking$626,733
R01 · FY2024 · CA · contact PI
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy$771,499
R01 · FY2023 · CA
Combination antigen sensing engineered T cell for precise recognition and enhanced elimination of solid tumors$666,104
R01 · FY2023 · CA · contact PI
Engineered T cell-based imaging for glioblastoma and CAR-T cell tracking$659,642
R01 · FY2023 · CA · contact PI
Smart Tumor Recognition$1,917,165
U54 · FY2019 · CA · contact PI
Engineering the Next-generation of Custom Immune Cell Therapies$2,415,750
DP2 · FY2018 · CA · contact PI